Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
May 4, 2020

Cerus Corporation receives FDA approval for disposable plasma kit

By Chloe Kent

Cerus Corporation has received US Food and Drug Administration (FDA) approval for the manufacture of its INTERCEPT plasma kit with a new, alternative plastic disposable kit.

The INTERCEPT Blood System for plasma is designed to reduce the presence of pathogens in plasma components. It has demonstrated robust inactivation of several members of the coronavirus family, including SARS-1 COV and MERS CoV.

The conversion of the kits to disposable is part of Cerus’s ongoing strategy to enhance the integrity of its global supply chain.

Cerus president and CEO William Greenman said: “The approval is important given the renewed interest in convalescent plasma as a promising treatment for those afflicted with Covid-19.”

Related Companies

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy